Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of LY4064809 in Healthy Chinese Participants
NCT07247357Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tersolisib in cancer, sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration at 14 days and Area Under the Concentration Versus Time Curve at 14 days. Started Oct 2025; status: completed.
02
Drugs
tersolisib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07247357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07247357.